Granalix BioTechnologies Overview
Granalix BioTechnologies was established to develop innovative, science-based formulations of natural antioxidants that can be used for the prevention and treatment of neurodegenerative conditions. The company's first product, GranaGard, is a submicron self-emulsion formulation of pomegranate seed oil, which contains high concentrations of punicic acid (PA), one of the strongest natural antioxidants. In the GranaGard formulation, PA has been shown to convert in vivo into conjugated linoleic acid, an established neuroprotector and mitochondrial activity modulator. GranaGard was shown to delay disease onset in a mouse model of genetic prion disease, which presents neurodegenerative features reminiscent of Alzheimer's disease, as well as to reduce disease burden in a mouse model of multiple sclerosis. All components of GranaGard are generally regarded as safe by the FDA.
Latest News
growth-positive
Studies show pomegranate supplement slows neurodegenerative diseases
An Israeli supplement derived from pomegranate seed oil, developed by Granalix Biotechnologies, has shown promise in improving cognitive function in multiple sclerosis patients. The patented GranaGard supplement, developed by researchers at Hadassah-Hebrew University Medical Center, has been found to improve learning ability, text comprehension, word recall, and categorization in a study of 30 patients. GranaGard, made with punicic acid-rich pomegranate seed oil, is marketed as a food supplement and is sold worldwide. The supplement seems to prevent or slow neurodegeneration and reduce symptoms caused by neurodegenerative diseases or aging. Further studies are planned to explore its potential benefits in Alzheimers patients and MS patients with early memory impairment.
Customers
growth-positive
https://www.jpost.com/israel-news/new-israeli-trial-to-check-if-pomegranate-oil-could-improve-memory-635782
Rambam Medical Centers Memory Clinic is conducting a clinical trial to test the impact of Omega 5 acid from pomegranate seed oil on patients with mild cognitive impairment. The trial aims to determine if GranaGard, a pomegranate oil extract, can slow down memory loss. The experiment will involve 100 patients and will last for 12 months. Half of the patients will receive GranaGard, while the other half will receive a placebo. The patients memory will be tested throughout the trial to track their improvement. The development of GranaGard was based on nanotechnology patented by Israeli biotechnology company Granalix. Previous trials have shown positive results in preventing cognitive deterioration due to multiple sclerosis. The trial is in response to the high prevalence of neurodegenerative diseases in the United States.
Customers
growth-positive
Nano-engineered pomegranate oil holds hope for brain disease, study shows
An Israeli study has found that multiple sclerosis patients taking a nano-engineered nutritional supplement made out of pomegranate oil showed significant cognitive improvement after just three months. The supplement was developed by Prof. Ruth Gabizon and Prof. Shlomo Magdassi and is marketed by Granalix Biotechnologies Ltd. The company sells its products directly to customers in Israel and abroad online and via distributors in Mexico, Paraguay and Greece. The firm is about to start a second clinical study with Rambam Hospital in Haifa to study the impact of the supplement on moderate and mild cognitive impairment of people with dementia.
CustomersExpand
growth-positive
https://www.jpost.com/HEALTH-SCIENCE/The-pomegranate-potential-539296
Researchers at Hadassah University Medical Center and Hebrew University have developed a food supplement called GranaGard, which contains high concentrations of punicic acid, a powerful natural antioxidant found in pomegranate seeds. The supplement, marketed by Granalix, is aimed at preventing or slowing the development of neurological disorders. The supplement has been approved by the US Food and Drug Administration and is being sold via the companys website and at some stores. The researchers are also testing the supplement on Parkinsons disease.
CustomersInvestment
growth-positive
Jewish New Year fruit may hold seeds of hope for brain disease sufferers
Granalix Biotechnologies has developed a food supplement called GranaGard, which contains pomegranate seed oil. The oil is rich in antioxidants, which can protect against the destruction of brain and body cells. The challenge is ensuring that the antioxidants reach the brain, as they are often broken down in the digestive system. GranaGard has been formulated to break down the oil into tiny particles that can slip through the liver undetected and make their way to the brain. Studies on lab mice have shown that GranaGard can delay the spread and intensity of degenerative brain diseases. The company is now planning to conduct clinical trials on humans with diseases such as Alzheimers and multiple sclerosis. GranaGard is already available for purchase as a dietary supplement.
Customers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Mature |
| Rounds | 0 |
| Investors | 0 |
Team Members
4
Employees: 1-10
Web & Social Links
| Website | il.granalix.com |
| Careers | Careers page |
Locations
Yad Harutsim Street 6, Jerusalem, Israel
Photos & Videos
2 item(s)
